MICOT PHARMA-B (02335) Announces First Patient Dosed in Phase Ib/II Trial for Acute Ischemic Stroke Treatment MT1002

Stock News07-03

MICOT PHARMA-B (ASX: 02335) has announced that the first patient has been successfully dosed in the Ib/II phase clinical trial for its self-developed investigational drug, MT1002, intended for the treatment of acute ischemic stroke (AIS). This milestone signifies the official entry of this pivotal registration study into its substantive execution phase.

This Ib/II phase clinical trial is divided into two parts. The first part is a multicenter clinical study evaluating the safety, efficacy, and pharmacokinetic profile of MT1002 in patients with acute ischemic stroke. The second part is a multicenter, randomized, standard-of-care controlled clinical study designed to assess the safety and efficacy of MT1002 in patients with acute ischemic stroke. The first patient dosing announced refers specifically to the first patient in the first part of this Ib/II phase trial.

Acute ischemic stroke is a clinical syndrome characterized by the sudden, severe narrowing or occlusion of a cerebral artery due to various causes, leading to local brain tissue ischemia, hypoxic necrosis, and corresponding neurological deficits, with new cerebral infarction changes visible on head CT or MRI. It is the most common type of stroke. A 2025 review on treatment advances for acute ischemic stroke reported that AIS accounts for 69.6% to 72.8% of new stroke cases in China.

According to data from industry sources, the market size for major acute-phase therapeutic drugs for ischemic stroke in China has consistently exceeded 10 billion yuan in recent years, reaching 12.9 billion yuan in 2023.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184437870?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 18:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184437870","market":"sh","top_or_hot":-1,"title":"MICOT PHARMA-B (02335) Announces First Patient Dosed in Phase Ib/II Trial for Acute Ischemic Stroke Treatment MT1002","media":"Stock News","content":"<p><b>MICOT PHARMA-B</b> (<b>ASX: 02335</b>) has announced that the first patient has been successfully dosed in the Ib/II phase clinical trial for its self-developed investigational drug, MT1002, intended for the treatment of acute ischemic stroke (AIS). This milestone signifies the official entry of this pivotal registration study into its substantive execution phase.<br><br>\nThis Ib/II phase clinical trial is divided into two parts. The first part is a multicenter clinical study evaluating the safety, efficacy, and pharmacokinetic profile of MT1002 in patients with acute ischemic stroke. The second part is a multicenter, randomized, standard-of-care controlled clinical study designed to assess the safety and efficacy of MT1002 in patients with acute ischemic stroke. The first patient dosing announced refers specifically to the first patient in the first part of this Ib/II phase trial.<br><br>\nAcute ischemic stroke is a clinical syndrome characterized by the sudden, severe narrowing or occlusion of a cerebral artery due to various causes, leading to local brain tissue ischemia, hypoxic necrosis, and corresponding neurological deficits, with new cerebral infarction changes visible on head CT or MRI. It is the most common type of stroke. A 2025 review on treatment advances for acute ischemic stroke reported that AIS accounts for 69.6% to 72.8% of new stroke cases in China.<br><br>\nAccording to data from industry sources, the market size for major acute-phase therapeutic drugs for ischemic stroke in China has consistently exceeded 10 billion yuan in recent years, reaching 12.9 billion yuan in 2023.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MICOT PHARMA-B (02335) Announces First Patient Dosed in Phase Ib/II Trial for Acute Ischemic Stroke Treatment MT1002</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMICOT PHARMA-B (02335) Announces First Patient Dosed in Phase Ib/II Trial for Acute Ischemic Stroke Treatment MT1002\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-03 18:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>MICOT PHARMA-B</b> (<b>ASX: 02335</b>) has announced that the first patient has been successfully dosed in the Ib/II phase clinical trial for its self-developed investigational drug, MT1002, intended for the treatment of acute ischemic stroke (AIS). This milestone signifies the official entry of this pivotal registration study into its substantive execution phase.<br><br>\nThis Ib/II phase clinical trial is divided into two parts. The first part is a multicenter clinical study evaluating the safety, efficacy, and pharmacokinetic profile of MT1002 in patients with acute ischemic stroke. The second part is a multicenter, randomized, standard-of-care controlled clinical study designed to assess the safety and efficacy of MT1002 in patients with acute ischemic stroke. The first patient dosing announced refers specifically to the first patient in the first part of this Ib/II phase trial.<br><br>\nAcute ischemic stroke is a clinical syndrome characterized by the sudden, severe narrowing or occlusion of a cerebral artery due to various causes, leading to local brain tissue ischemia, hypoxic necrosis, and corresponding neurological deficits, with new cerebral infarction changes visible on head CT or MRI. It is the most common type of stroke. A 2025 review on treatment advances for acute ischemic stroke reported that AIS accounts for 69.6% to 72.8% of new stroke cases in China.<br><br>\nAccording to data from industry sources, the market size for major acute-phase therapeutic drugs for ischemic stroke in China has consistently exceeded 10 billion yuan in recent years, reaching 12.9 billion yuan in 2023.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBBQ","symbol_name":"Invesco Nasdaq Biotechnology ETF","start_time":0,"source_url":"","article_id":"1184437870","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184437870","pubTimestamp":1783074992,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MICOT PHARMA-B (ASX: 02335) has announced that the first patient has been successfully dosed in the Ib/II phase clinical trial for its self-developed investigational drug, MT1002, intended for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBBQ":"Invesco Nasdaq Biotechnology ETF","BMED":"iShares Health Innovation Active ETF","02335":"麦科医药-B"},"translate_title":"MICOT PHARMA-B(02335)宣布急性缺血性卒中治疗MT1002 Ib/II期试验首例患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBBQ":1,"BMED":1,"02335":1},"content_text":"MICOT PHARMA-B (ASX: 02335) has announced that the first patient has been successfully dosed in the Ib/II phase clinical trial for its self-developed investigational drug, MT1002, intended for the treatment of acute ischemic stroke (AIS). This milestone signifies the official entry of this pivotal registration study into its substantive execution phase.\nThis Ib/II phase clinical trial is divided into two parts. The first part is a multicenter clinical study evaluating the safety, efficacy, and pharmacokinetic profile of MT1002 in patients with acute ischemic stroke. The second part is a multicenter, randomized, standard-of-care controlled clinical study designed to assess the safety and efficacy of MT1002 in patients with acute ischemic stroke. The first patient dosing announced refers specifically to the first patient in the first part of this Ib/II phase trial.\nAcute ischemic stroke is a clinical syndrome characterized by the sudden, severe narrowing or occlusion of a cerebral artery due to various causes, leading to local brain tissue ischemia, hypoxic necrosis, and corresponding neurological deficits, with new cerebral infarction changes visible on head CT or MRI. It is the most common type of stroke. A 2025 review on treatment advances for acute ischemic stroke reported that AIS accounts for 69.6% to 72.8% of new stroke cases in China.\nAccording to data from industry sources, the market size for major acute-phase therapeutic drugs for ischemic stroke in China has consistently exceeded 10 billion yuan in recent years, reaching 12.9 billion yuan in 2023.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184437870","isCrawlerRequest":true}